NASDAQ · STOCK
Regeneron Pharmaceuticals
$664.56
52W $541.00 – $821.11
65/100
$70.03B
15.8
0.21
Price History (6M)
Executive Summary
5 analysts weighed in with 60% agreement on a bullish lean. Portfolio Manager: Portfolio position concentration is currently healthy. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
65/100
Agreement
60%
Analysts
5
Conviction
Moderate
Growth Analyst
neutral
58
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
65.3
Neutral
MACD Histogram
7.487
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$645.19
Resistance
$747.75
Bollinger %B
0.87
Inside Bands
Price vs Moving Averages
EMA 9
$653.38
Above
EMA 21
$642.18
Above
EMA 50
$655.95
Above
EMA 200
$689.63
Below
Fundamental Analysis
Valuation
90
Growth
50
Profitability
93
Financial Health
100
Valuation
P/E Ratio
15.8×
P/B Ratio
2.60×
PEG Ratio
—
Dividend Yield
0.57%
52W High
$821.11
52W Low
$541.00
Quality & Growth
ROE
1432.0%
ROA
1107.0%
Gross Margin
8570.0%
Operating Margin
2432.0%
Revenue Growth YoY
+592.0%
Debt / Equity
0.09
AI Fundamental Assessment
P/E ratio of 15.8 (inexpensive relative to a 15-40x range); Price-to-book of 2.6x; Revenue growth (YoY) of 5.9%; EPS growth (YoY) of 4.4%; Return on equity of 14.3%; Return on assets of 11.1%; Net margin of 29.6%; Gross margin of 85.7%; Current ratio of 4.13 (healthy short-term liquidity); Debt-to-equity of 0.09; Most recent quarter beat estimates by 3.9%; 4 consecutive earnings beats; EPS growth decelerating (-3.3% -> -17.2% QoQ); Analyst estimates falling over recent quarters
Key Risks
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full REGN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile